<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00898807</url>
  </required_header>
  <id_info>
    <org_study_id>IA0155</org_study_id>
    <secondary_id>R01AG031348</secondary_id>
    <nct_id>NCT00898807</nct_id>
  </id_info>
  <brief_title>Citalopram for Agitation in Alzheimer's Disease</brief_title>
  <acronym>CitAD</acronym>
  <official_title>A Multi-Center Randomized Placebo-Controlled Clinical Trial Study of Citalopram for the Treatment of Agitation in Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JHSPH Center for Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>JHSPH Center for Clinical Trials</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of citalopram for agitation
      in Alzheimer's dementia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to examine the efficacy and safety of citalopram as treatment for
      clinically significant agitation in Alzheimer's dementia (AD) patients. It will also
      investigate pharmacogenomic, genetic, and clinical predictors of response to citalopram
      therapy. The management of agitation is a major priority in treating patients with AD.
      Non-pharmacologic options have limited effectiveness. Several pharmacologic options have been
      explored, but findings for anticonvulsants, antipsychotics, and cholinesterase inhibitors are
      disappointing or associated with questionable risk-benefit ratio. Better pharmacologic
      options are needed. Selective serotonin reuptake inhibitors (SSRIs) show promise as a
      treatment for agitation in AD, based on evidence of a link between agitation and brain
      serotonin system abnormalities in AD patients, and on preliminary clinical data from a
      single-site, randomized controlled trial (RCT) in which citalopram was superior to
      perphenazine and placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NeuroBehavior Rating Scale-- Agitation</measure>
    <time_frame>9 weeks</time_frame>
    <description>NeuroBehavioral Rating Scale- Agitation(NBRS-A) assesses multiple types of psychopathology common in dementia and is based on a seven point Likert scale of increasing severity for each item(i.e., 0=not present, 1=very mild, 2-mild, 3=moderate, 4=moderately severe, 5=severe, 6=extremely severe). The NBRS agitation subscore includes NBRS 'inhibition', 'agitation', and 'hostility'. The range is 0 to 18 points. Higher scores indicate more symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Modified Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change in Agitation(CGIC)</measure>
    <time_frame>Baseline to 9 weeks</time_frame>
    <description>Modified Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change in agitation(CGIC) accesses clinically significant change in agitation. A trained clinician, blind to treatment assignment, uses a 7-point Likert scale to rate change of each patient along a continuum from &quot;marked improvement&quot;(1), &quot;no change&quot;(4), and &quot;marked worsening&quot;(7). A number of aspects of the agitation is considered such as emotional agitation, mood liability/distress, psychomotor agitation, verbal aggression, and physical aggression. Range is 1-7.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cohen-Mansfield Agitation Inventory (CMAI)</measure>
    <time_frame>9 weeks</time_frame>
    <description>CMAI examines several agitated behaviors including verbal, physical agitation, and other behaviors. Sub-items are summed. Range is 14-70. Higher scores indicate more severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric Inventory (NPI)-- Agitation Subscore</measure>
    <time_frame>9 weeks</time_frame>
    <description>NPI agitation score is based on responses from an informed caregiver involved in the patient's life. Symptom severity (1=mild, 2=moderate, 3=severe) is multiplied by frequency (1=occasionally, less than once/week; 4 = very frequently, once or more/day or continuously) to obtain the NPI agitation score.Range is 0-12. Higher scores indicate more severe symptoms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">186</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Agitation</condition>
  <arm_group>
    <arm_group_label>Citalopram and psychosocial intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Target dose of 30 mg per day of citalopram, oral, and psychosocial intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and psychosocial intervention</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo, oral, and psychosocial intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>citalopram</intervention_name>
    <description>target dose 30mg daily for 9 weeks</description>
    <arm_group_label>Citalopram and psychosocial intervention</arm_group_label>
    <other_name>Celexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>daily for 9 weeks</description>
    <arm_group_label>Placebo and psychosocial intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  Probable Alzheimer's disease (National Institute of Neurological and Communicative
             Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association
             criteria), with Mini-Mental score of 5-28 inclusive

          -  A medication for agitation is appropriate, in the opinion of the study physician

          -  Clinically significant agitation for which either

               1. the frequency of agitation as assessed by the Neuropsychiatric Inventory (NPI) is
                  'Very frequently', or

               2. the frequency of agitation as assessed by the NPI is 'Frequently' AND the
                  severity of the agitation as assessed by the NPI is 'Moderate', or 'Marked'

          -  Provision of informed consent for participation in the study by patient or surrogate
             (if necessary) and caregiver

          -  Availability of primary caregiver, who spends several hours a week with the patient
             and supervises his/her care, to accompany the patient to study visits and to
             participate in the study

          -  No change to Alzheimer's disease (AD) medications within the month preceding
             randomization, including starting, stopping, or dosage modifications

        Exclusion criteria

          -  Meets criteria for Major Depressive Episode by Diagnostic and Statistical Manual of
             Mental Disorders, 4th edition, text revision (DSM-IV (TR)) criteria

          -  Presence of a brain disease that might otherwise explain the presence of dementia,
             such as extensive brain vascular disease, Parkinson's disease, dementia with Lewy
             bodies, traumatic brain injury, or multiple sclerosis

          -  Psychosis (delusions or hallucinations) requiring antipsychotic treatment in the
             opinion of the study physician

          -  Prolonged measure of the time between the start of the Q wave and the end of the T
             wave in the heart's electrical cycle (QT interval)

          -  Treatment with citalopram is contraindicated in the opinion of the study physician

          -  Failure of past treatment with citalopram for agitation after adequate trial at a
             minimally accepted dose (greater than or equal to 20 mg/day)

          -  Treatment with a medication that would prohibit the safe concurrent use of citalopram,
             such as Monoamine oxidases (MAO) inhibitors

          -  Need for psychiatric hospitalization or suicidal

          -  Current participation in a clinical trial or in any study that may add a significant
             burden or affect neuropsychological or other study outcomes

          -  Current treatment with antipsychotics, anticonvulsants (other than dilantin), other
             antidepressants (other than trazodone, less than or equal to 50 mg per day at
             bedtime), benzodiazepines (other than lorazepam), or psychostimulants

          -  Any condition that, in the opinion of the study physician, makes it medically
             inappropriate or risky for the patient to enroll in the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Constantine Lyketsos, MD, MHS</last_name>
    <role>Study Chair</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lon Schneider, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California Keck School of Medicine Memory and Aging Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruce Pollock, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Addiction and Mental Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacobo Mintzer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina Alzheimer's Research and Clinical Programs</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Shade, Esq</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Davengere Devanand, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Rosenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Weintraub, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anton Porsteinsson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jerome Yesavage, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California Keck School of Medicine Memory and Aging Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Palo Alto Health Care System</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monroe Community Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14559</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Section of Geriatric Psychiatry, Ralston House</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina Alzheimer's Research and Clinical Programs</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6J1H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Drye LT, Ismail Z, Porsteinsson AP, Rosenberg PB, Weintraub D, Marano C, Pelton G, Frangakis C, Rabins PV, Munro CA, Meinert CL, Devanand DP, Yesavage J, Mintzer JE, Schneider LS, Pollock BG, Lyketsos CG; CitAD Research Group. Citalopram for agitation in Alzheimer's disease: design and methods. Alzheimers Dement. 2012;8(2):121-30. doi: 10.1016/j.jalz.2011.01.007. Epub 2012 Feb 1.</citation>
    <PMID>22301195</PMID>
  </reference>
  <results_reference>
    <citation>Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Rosenberg PB, Schneider LS, Shade DM, Weintraub D, Yesavage J, Lyketsos CG; CitAD Research Group. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014 Feb 19;311(7):682-91. doi: 10.1001/jama.2014.93.</citation>
    <PMID>24549548</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2009</study_first_submitted>
  <study_first_submitted_qc>May 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <results_first_submitted>March 19, 2014</results_first_submitted>
  <results_first_submitted_qc>June 26, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 27, 2014</results_first_posted>
  <last_update_submitted>June 26, 2014</last_update_submitted>
  <last_update_submitted_qc>June 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Dave Shade</investigator_full_name>
    <investigator_title>Director of CitAD Coordinating Center</investigator_title>
  </responsible_party>
  <keyword>neuropsychiatric symptoms</keyword>
  <keyword>aggression</keyword>
  <keyword>mood lability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment activities included chart review, telephone interviews and screens, discussion with physicians, and recruitment in the clinic waiting areas and assisted living facilities affiliated with the clinics. The recruitment period lasted from August 2009 to December 2012.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Citalopram and Psychosocial Intervention</title>
          <description>Target dose of 30 mg per day of citalopram, oral, and psychosocial intervention
citalopram : target dose 30mg daily for 9 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo and Psychosocial Intervention</title>
          <description>Matching placebo, oral, and psychosocial intervention
placebo : daily for 9 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Family pressure to discontinue</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Citalopram and Psychosocial Intervention</title>
          <description>Target dose of 30 mg per day of citalopram, oral, and psychosocial intervention
citalopram : target dose 30mg daily for 9 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo and Psychosocial Intervention</title>
          <description>Matching placebo, oral, and psychosocial intervention
placebo : daily for 9 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="94"/>
            <count group_id="B2" value="92"/>
            <count group_id="B3" value="186"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78" spread="9"/>
                    <measurement group_id="B2" value="79" spread="8"/>
                    <measurement group_id="B3" value="78" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>NeuroBehavior Rating Scale-- Agitation</title>
        <description>NeuroBehavioral Rating Scale- Agitation(NBRS-A) assesses multiple types of psychopathology common in dementia and is based on a seven point Likert scale of increasing severity for each item(i.e., 0=not present, 1=very mild, 2-mild, 3=moderate, 4=moderately severe, 5=severe, 6=extremely severe). The NBRS agitation subscore includes NBRS 'inhibition’, ‘agitation’, and ‘hostility’. The range is 0 to 18 points. Higher scores indicate more symptoms.</description>
        <time_frame>9 weeks</time_frame>
        <population>The primary analysis was an intention-to-treat analysis; analysis was conducted &quot;as randomized&quot;. Data from the 186 randomized participants were used in the analytic model. 167 of the 186 patients had week 9 data on the NBRS.</population>
        <group_list>
          <group group_id="O1">
            <title>Citalopram and Psychosocial Intervention</title>
            <description>Target dose of 30 mg per day of citalopram, oral, and psychosocial intervention
citalopram : target dose 30mg daily for 9 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Psychosocial Intervention</title>
            <description>Matching placebo, oral, and psychosocial intervention
placebo : daily for 9 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>NeuroBehavior Rating Scale-- Agitation</title>
          <description>NeuroBehavioral Rating Scale- Agitation(NBRS-A) assesses multiple types of psychopathology common in dementia and is based on a seven point Likert scale of increasing severity for each item(i.e., 0=not present, 1=very mild, 2-mild, 3=moderate, 4=moderately severe, 5=severe, 6=extremely severe). The NBRS agitation subscore includes NBRS 'inhibition’, ‘agitation’, and ‘hostility’. The range is 0 to 18 points. Higher scores indicate more symptoms.</description>
          <population>The primary analysis was an intention-to-treat analysis; analysis was conducted &quot;as randomized&quot;. Data from the 186 randomized participants were used in the analytic model. 167 of the 186 patients had week 9 data on the NBRS.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.33" spread="0.31"/>
                    <measurement group_id="O2" value="5.26" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary assessment of efficacy was based on intention-to-treat comparison of the difference in the NBRS-A scores at week 9 and comparison at week 9 for the CGIC. For the NBRS-A, the study was designed to have 85% power to detect a standardized difference at week 9 of 40% for citalopram compared to placebo at week 9.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.036</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons. All p-values are two-sided and p&lt;0.05 was the threshold for statistical significance.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>Mixed effects model w/ random intercept for patient, visit indicator, treatment by visit interactions and adjusted for baseline NBRS-A &amp; cognition.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.80</ci_lower_limit>
            <ci_upper_limit>-0.06</ci_upper_limit>
            <estimate_desc>Negative numbers favor citalopram group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Modified Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change in Agitation(CGIC)</title>
        <description>Modified Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change in agitation(CGIC) accesses clinically significant change in agitation. A trained clinician, blind to treatment assignment, uses a 7-point Likert scale to rate change of each patient along a continuum from “marked improvement”(1), “no change”(4), and “marked worsening”(7). A number of aspects of the agitation is considered such as emotional agitation, mood liability/distress, psychomotor agitation, verbal aggression, and physical aggression. Range is 1-7.</description>
        <time_frame>Baseline to 9 weeks</time_frame>
        <population>The primary analysis was an intention-to-treat analysis; analysis was conducted &quot;as randomized&quot;. Data from the 186 randomized participants were used in the analytic model. 167 of the 186 patients had week 9 data on CGIC.</population>
        <group_list>
          <group group_id="O1">
            <title>Citalopram and Psychosocial Intervention</title>
            <description>Target dose of 30 mg per day of citalopram, oral, and psychosocial intervention
citalopram : target dose 30mg daily for 9 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Psychosocial Intervention</title>
            <description>Matching placebo, oral, and psychosocial intervention
placebo : daily for 9 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Modified Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change in Agitation(CGIC)</title>
          <description>Modified Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change in agitation(CGIC) accesses clinically significant change in agitation. A trained clinician, blind to treatment assignment, uses a 7-point Likert scale to rate change of each patient along a continuum from “marked improvement”(1), “no change”(4), and “marked worsening”(7). A number of aspects of the agitation is considered such as emotional agitation, mood liability/distress, psychomotor agitation, verbal aggression, and physical aggression. Range is 1-7.</description>
          <population>The primary analysis was an intention-to-treat analysis; analysis was conducted &quot;as randomized&quot;. Data from the 186 randomized participants were used in the analytic model. 167 of the 186 patients had week 9 data on CGIC.</population>
          <units>percentage moderate/marked improvement</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Primary assessment of efficacy was based on intention-to-treat comparison of the difference in the NBRS-A scores at week 9 and comparison at week 9 for the CGIC. For the CGIC proportional odds analysis, the study was designed to have power greater than 80% to detect a difference of 20% between citalopram and placebo in the proportions of patients who improve (or worsen).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <p_value_desc>All p-values are two-sided and p &lt;0.05 was the threshold for statistical significance. No adjustments were made for multiple comparisons.</p_value_desc>
            <method>Proportional odds</method>
            <method_desc>estimated treatment effect from the proportional odds model</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.23</ci_lower_limit>
            <ci_upper_limit>3.69</ci_upper_limit>
            <estimate_desc>Positive numbers favors citalopram.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohen-Mansfield Agitation Inventory (CMAI)</title>
        <description>CMAI examines several agitated behaviors including verbal, physical agitation, and other behaviors. Sub-items are summed. Range is 14-70. Higher scores indicate more severe symptoms.</description>
        <time_frame>9 weeks</time_frame>
        <population>The primary analysis was an intention-to-treat analysis; analysis was conducted &quot;as randomized&quot;. Data from the 186 randomized participants were used in the analytic model. 169 of the 186 patients had week 9 data.</population>
        <group_list>
          <group group_id="O1">
            <title>Citalopram and Psychosocial Intervention</title>
            <description>Target dose of 30 mg per day of citalopram, oral, and psychosocial intervention
citalopram : target dose 30mg daily for 9 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Psychosocial Intervention</title>
            <description>Matching placebo, oral, and psychosocial intervention
placebo : daily for 9 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Cohen-Mansfield Agitation Inventory (CMAI)</title>
          <description>CMAI examines several agitated behaviors including verbal, physical agitation, and other behaviors. Sub-items are summed. Range is 14-70. Higher scores indicate more severe symptoms.</description>
          <population>The primary analysis was an intention-to-treat analysis; analysis was conducted &quot;as randomized&quot;. Data from the 186 randomized participants were used in the analytic model. 169 of the 186 patients had week 9 data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7" spread="6.7"/>
                    <measurement group_id="O2" value="28.7" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neuropsychiatric Inventory (NPI)-- Agitation Subscore</title>
        <description>NPI agitation score is based on responses from an informed caregiver involved in the patient's life. Symptom severity (1=mild, 2=moderate, 3=severe) is multiplied by frequency (1=occasionally, less than once/week; 4 = very frequently, once or more/day or continuously) to obtain the NPI agitation score.Range is 0-12. Higher scores indicate more severe symptoms.</description>
        <time_frame>9 weeks</time_frame>
        <population>The primary analysis was an intention-to-treat analysis; analysis was conducted &quot;as randomized&quot;. Data from the 186 randomized participants were used in the analytic model. 169 of the 186 patients had week 9 data.</population>
        <group_list>
          <group group_id="O1">
            <title>Citalopram and Psychosocial Intervention</title>
            <description>Target dose of 30 mg per day of citalopram, oral, and psychosocial intervention
citalopram : target dose 30mg daily for 9 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Psychosocial Intervention</title>
            <description>Matching placebo, oral, and psychosocial intervention
placebo : daily for 9 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Neuropsychiatric Inventory (NPI)-- Agitation Subscore</title>
          <description>NPI agitation score is based on responses from an informed caregiver involved in the patient's life. Symptom severity (1=mild, 2=moderate, 3=severe) is multiplied by frequency (1=occasionally, less than once/week; 4 = very frequently, once or more/day or continuously) to obtain the NPI agitation score.Range is 0-12. Higher scores indicate more severe symptoms.</description>
          <population>The primary analysis was an intention-to-treat analysis; analysis was conducted &quot;as randomized&quot;. Data from the 186 randomized participants were used in the analytic model. 169 of the 186 patients had week 9 data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="2.2"/>
                    <measurement group_id="O2" value="8.0" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events (AEs) are collected systematically on the follow-up visit form; therefore, numbers of participants at risk for AEs reflect at least on follow-up visit form completed. Serious adverse events are often self-reported and can be collected any time throughout the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Citalopram and Psychosocial Intervention</title>
          <description>Target dose of 30 mg per day of citalopram, oral, and psychosocial intervention
citalopram : target dose 30mg daily for 9 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo and Psychosocial Intervention</title>
          <description>Matching placebo, oral, and psychosocial intervention
placebo : daily for 9 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Surgical removal of infected plate in wrist</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status change</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
              <event>
                <sub_title>Increased agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="92"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Indigestion</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Drug allergy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Muscle pain</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Gait instability</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Yawning</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Falls</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Visual disturbance</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Deceased libido</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Suicidal thoughts</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ejaculatory dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anne Casper</name_or_title>
      <organization>Johns Hopkins</organization>
      <phone>410-955-8183</phone>
      <email>ashankl1@jhu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

